Ultragenyx Pharmaceutical Inc  

(Public, NASDAQ:RARE)   Watch this stock  
Find more results for RARE
103.86
0.00 (0.00%)
Jul 1 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 37.77 - 105.97
Open     -
Vol / Avg. 0.00/500,625.00
Mkt cap 3.73B
P/E     -
Div/yield     -
EPS -2.11
Shares 35.90M
Beta     -
Inst. own 88%
Aug 10, 2015
Q2 2015 Ultragenyx Pharmaceutical Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 24, 2015
Ultragenyx Pharmaceutical Inc at JMP Securities Life Sciences Conference
Jun 18, 2015
Ultragenyx Pharmaceutical Inc Annual Shareholders Meeting - Webcast
Jun 2, 2015
Ultragenyx Pharmaceutical Inc at Jefferies Global Healthcare Conference
May 11, 2015
Q1 2015 Ultragenyx Pharmaceutical Inc Earnings Call - Webcast
May 11, 2015
Q1 2015 Ultragenyx Pharmaceutical Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -30.97% -46.43%
Return on average equity -32.60% -117.34%
Employees 140 -
CDP Score - -

Address

60 Leveroni Ct
NOVATO, CA 94949-5746
United States - Map
+1-415-4838800 (Phone)
+1-415-4838810 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Its pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies. Its products are KRN23 (UX023), rhGUS (UX003), rhPPCA (UX004), Triheptanoin (UX007) and SA-ER (UX001). KRN23 is a fully human monoclonal antibody administered via subcutaneous injection. rhGUS is an intravenous (IV), enzyme replacement therapy for the treatment of mucopolysaccharidosis 7. rhPPCA is an enzyme replacement therapy for galactosialidosis. Triheptanoin is a medium odd-chain triglyceride of seven-carbon fatty acids. SA-ER is for the treatment of hereditary inclusion body myopathy (HIBM).

Officers and directors

Emil D. Kakkis M.D., Ph.D. President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Shalini Sharp Senior Vice President, Chief Financial Officer
Age: 40
Bio & Compensation  - Reuters
Sunil Agarwal M.D. Chief Medical Officer, Senior Vice President
Age: 45
Bio & Compensation  - Reuters
Dennis Huang Chief Technical Operations Officer and Senior Vice President
Bio & Compensation  - Reuters
Thomas Kassberg Senior Vice President, Chief Business Officer
Age: 54
Bio & Compensation  - Reuters
William E. Aliski Independent Director
Age: 67
Bio & Compensation  - Reuters
Matthew K. Fust Independent Director
Age: 50
Bio & Compensation  - Reuters
Michael A. Narachi Independent Director
Age: 55
Bio & Compensation  - Reuters
Clay B. Siegall Ph.D. Independent Director
Age: 54
Bio & Compensation  - Reuters
Daniel G. Welch Independent Director
Age: 57
Bio & Compensation  - Reuters